SESSION V - 11:00 AM to 12:45 PM

SESSION DESCRIPTION

The patient perspective is critical in delivering care, achieving outcomes and measuring what matters to patients. This session discusses the unique value patients bring to measuring, reporting, and comparing healthcare outcomes – and how they should be meaningfully involved throughout the process.

Session Code: FGS-3

SPEAKERS

John A. Galdo (Jake), PharmD, MBA, BCPS, BCGP
Director, Education and Program Development, Pharmacy Quality Alliance
Katherine Capperella
Global Head Patient Engagement Leader, Janssen
Suzanne Schrandt, JD
CEO, & Chief Patient Advocate, ExPPect

SESSION DESCRIPTION

In the pediatric population, second-generation antipsychotic medications are approved for diagnoses of autism, schizophrenia and bipolar disorder and are often used for off-label indications. During the past decade, an overall increase in pediatric use of second generation atypical antipsychotic medications has occurred due to convincing evidence that this class of medications is effective for reducing aggression and irritability in this population with psychiatric disorders. Up to 1 out of 5 (13-20%) children experience a mental disorder in a given year. The use of concurrent antipsychotic medications increases the likelihood of adverse drug reactions and the risk of drug-drug interactions. Antipsychotic medications can also cause weight gain, drowsiness and increase the risk of developing hyperglycemia, hyperlipidemia, and hyperprolactinemia.

Safe and effective use of this class of medications depends on appropriate medication monitoring. Provider adherence to medication monitoring is low due to barriers which include: familiarity with ordering and interpreting results, and confusion over responsibility for metabolic monitoring.

For these reasons, children and adolescents on antipsychotic medications can benefit significantly from a pharmacist-led drug therapy management (DTM) program. Our targeted DTM program monitors patients on behavioral health medications, focusing on appropriate specialist follow up, laboratory values, drug-drug interactions, adverse drug effects, adherence, and optimizing medication regimens. Pharmacists work with patients, their legal guardians, providers, and case managers to assist in these medication-related problems to ultimately improve member outcomes, decrease overall healthcare expenditures, and close gaps in care.

LEARNING OBJECTIVES

1. Identify the need of medication monitoring for children and adolescents on antipsychotic agents.
2. Describe a behavioral health drug therapy management (DTM) program.
3. Explain how a PBM clinical pharmacist team can impact behavioral health medication management.

Session Code: F1-Q1-C

ACPE UAN: 0221-9999-20-251-L04-P
Contact Hours of Credit: 0.35

SPEAKERS

Jenny Cheung, PharmD, BCACP
Clinical Pharmacist, PerformRx
Binal Patel, MPharm, BCGP
Director, Clinical Outcomes & Therapeutic Optimization, PerformRx

SESSION DESCRIPTION

Osteoporosis is associated with significant burden in older adults. As per the HEDIS measure on osteoporosis management in women who had a fracture, only 39-47% of women received appropriate care in 2017. Despite its low performance and the resulting burden, there is a lack of critical evidence evaluating the impact of this measure on outcomes. Additionally, this measure also excludes men. However, men have higher rates of morbidity and mortality following a fragility fracture, and nearly a third experience subsequent fractures. Osteoporosis in men is severely underdiagnosed and undertreated. Results from Medicare administrative claims data will be presented to evaluate relationship to outcomes such as subsequent fracture and all-cause mortality. This session will introduce attendees to the treatment guidelines and quality measures in osteoporosis, present results from an analysis of Medicare data, and make recommendations for the future of quality measurement in osteoporosis.

LEARNING OBJECTIVES

1. Review the latest clinical guidelines for the identification and management of osteoporosis among men and women.
2. Explain and critically evaluate the performance of existing quality measures in the management of osteoporosis among older adults.
3. Identify gaps in the measurement of quality of care for the management of osteoporosis among older adults.

Session Code: F2-Q1-B

ACPE UAN: 0221-9999-20-252-L04-P
Contact Hours of Credit: 0.35

SPEAKERS

Sujith Ramachandran, PhD
Assistant Professor, University of Mississippi School of Pharmacy
Yiqiao Zhang, MS
Graduate Research Assistant, University of Mississippi School of Pharmacy

SESSION DESCRIPTION

Session Code: FGS-4

SPEAKERS

Laura Cranston, RPh
CEO, Pharmacy Quality Alliance